BM Psaty, NL Smith, DS Siscovick, TD … - Jama, 1997 - Am Med Assoc OBJECTIVE: To review the scientific evidence concerning the safety and efficacy
of various antihypertensive therapies used as first-line agents and evaluated in
terms of major disease end points. DATA SOURCES: MEDLINE searches and ... Cited by 863 - Related articles - BL Direct - All 5 versions
DK Heyland, F Novak, JW Drover, M Jain, X … - Jama, 2001 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Should Immunonutrition ... Cited by 607 - Related articles - BL Direct - All 6 versions
ML Kamb, M Fishbein, JM Douglas Jr, F Rhodes … - Jama, 1998 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Context.— The efficacy ... Cited by 571 - Related articles - BL Direct - All 8 versions
- ►highwire.org M Egger, B Hirschel, P Francioli, P Sudre, M … - Bmj, 1997 - bmjcom.highwire.org You are seeing this message because your web browser does not support basic web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Objectives: To examine ... Cited by 470 - Related articles - BL Direct - All 8 versions
- ►critcaremed.com F Novak, DK Heyland, A Avenell, JW Drover, … - Critical Care Medicine, 2002 - journals.lww.com Objective: To examine the relationship between glutamine supplementation and
hospital length of stay, complication rates, and mortality in patients
undergoing surgery and experiencing critical illness. Data Sources: ... Cited by 443 - Related articles - BL Direct - All 8 versions
DK Heyland, S MacDonald, L Keefe, JW … - Jama, 1998 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Context.— Nutritional ... Cited by 388 - Related articles - BL Direct - All 5 versions
- ►shouxi.net A Dibra, A Kastrati, J Mehilli, J Pache, H … - The New England journal of medicine, 2005 - nejm.highwire.org Methods We enrolled 250 patients with diabetes and coronary artery disease: 125
were randomly assigned to receive paclitaxel-eluting stents, and 125 to receive
sirolimus-eluting stents. The primary end point was in-segment late luminal ... Cited by 321 - Related articles - BL Direct - All 13 versions
- ►onlinejacc.org KW Mahaffey, JA Puma, NA Barbagelata, MF … - Journal of the American College of Cardiology, 1999 - Elsevier The AMISTAD trial was a prospective, open-label trial of thrombolysis with
randomization to adenosine or placebo in 236 patients within 6 h of infarction
onset. The primary end point was infarct size as determined by Tc-99 m ... Cited by 308 - Related articles - BL Direct - All 14 versions
- ►oxfordjournals.org AV D'Amico, JW Moul, PR Carroll, L Sun, D … - JNCI Journal of the National Cancer Institute, 2003 - jnci.oxfordjournals.org Background: The relationship between prostate-specific antigen (PSA)–defined
recurrence and prostate cancer–specific mortality remains unclear. Therefore,
we evaluated the hypothesis that a short post-treatment PSA doubling time ... Cited by 275 - Related articles - BL Direct - All 9 versions
CE Frangakis, DB Rubin - Biometrics, 2002 - jstor.org SUMMARY. Many scientific problems require that treatment comparisons be adjusted
for posttreatment variables, but the estimands underlying standard methods are
not causal effects. To address this deficiency, we propose a general ... Cited by 277 - Related articles - BL Direct - All 6 versions
